Congress Wealth Management LLC DE Purchases Shares of 7,840 Sanofi (NASDAQ:SNY)

Congress Wealth Management LLC DE bought a new position in Sanofi (NASDAQ:SNY - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 7,840 shares of the company's stock, valued at approximately $378,000.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Synergy Asset Management LLC acquired a new position in shares of Sanofi in the fourth quarter worth $25,000. McClarren Financial Advisors Inc. increased its position in Sanofi by 952.6% in the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company's stock worth $28,000 after purchasing an additional 543 shares during the last quarter. Lee Danner & Bass Inc. acquired a new position in Sanofi in the 4th quarter worth about $31,000. Sunbelt Securities Inc. raised its stake in shares of Sanofi by 72.1% during the 3rd quarter. Sunbelt Securities Inc. now owns 747 shares of the company's stock worth $43,000 after purchasing an additional 313 shares in the last quarter. Finally, Sierra Ocean LLC acquired a new stake in shares of Sanofi during the 4th quarter valued at about $44,000. Hedge funds and other institutional investors own 14.04% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on SNY shares. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a "sell" rating to a "hold" rating in a research note on Thursday, January 30th. The Goldman Sachs Group began coverage on Sanofi in a research report on Friday, March 21st. They issued a "neutral" rating and a $65.00 price target for the company. Sanford C. Bernstein raised Sanofi to a "strong-buy" rating in a report on Thursday, January 30th. Finally, StockNews.com lowered Sanofi from a "buy" rating to a "hold" rating in a report on Thursday, December 12th. Three equities research analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $62.50.

Remove Ads

Sanofi Stock Performance

Shares of Sanofi stock traded down $1.12 during midday trading on Tuesday, hitting $54.34. The company had a trading volume of 3,810,197 shares, compared to its average volume of 2,272,262. The stock has a market cap of $137.91 billion, a PE ratio of 21.82, a P/E/G ratio of 1.01 and a beta of 0.58. Sanofi has a 1-year low of $45.22 and a 1-year high of $60.12. The business's 50 day simple moving average is $55.22 and its two-hundred day simple moving average is $52.75. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, meeting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. As a group, equities analysts predict that Sanofi will post 4.36 EPS for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.